1. ARIA (amyloid-related imaging abnormalities) were more frequent in donanemab-treated patients with early symptomatic Alzheimer's disease compared to placebo. 
2. ARIA is an adverse event associated with donanemab treatment, requiring safety monitoring. 
3. Six independent baseline risk factors for ARIA-E were identified. 
4. Early MRI scans were emphasized to monitor and enhance safety. 
5. A 4-week MRI scan was added to the TRAILBLAZER-ALZ 2 protocol, reducing the risk of symptomatic ARIA-E by 36.3%.
6. Serious ARIA-E was reported in 1.5% of donanemab-treated participants.

Source: JAMA Neurology